首页 产品目录 分子砌块 按反应类型 1,2,4-三唑 (2S,5S,8S,11S,14S,23S)-23-((6S,9S,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54S)-21,45-bis((1H-indol-3-yl)methyl)-1,6-diamino-30-(2-amino-2-oxoethyl)-9,27-bis(3-amino-3-oxopropyl)-15,42,48,51-tetrakis(4-aminobutyl)-24-benzyl-12,18-di((S)-sec-butyl)-33,36-bis(3-guanidinopropyl)-54-(hydroxymethyl)-1-imino-39-(2-(methylthio)ethyl)-7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52-hexadecaoxo-2,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53-heptadecaazapentapentacontan-55-amido)-8-(carboxymethyl)-2-(hydroxymethyl)-5,11-bis(2-(methylthio)ethyl)-4,7,10,13,16,19,22-heptaoxo-14-(4-(phosphonooxy)benzyl)-3,6,9,12,15,18,21-heptaazapentacosanedioic acid

(2S,5S,8S,11S,14S,23S)-23-((6S,9S,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54S)-21,45-bis((1H-indol-3-yl)methyl)-1,6-diamino-30-(2-amino-2-oxoethyl)-9,27-bis(3-amino-3-oxopropyl)-15,42,48,51-tetrakis(4-aminobutyl)-24-benzyl-12,18-di((S)-sec-butyl)-33,36-bis(3-guanidinopropyl)-54-(hydroxymethyl)-1-imino-39-(2-(methylthio)ethyl)-7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52-hexadecaoxo-2,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53-heptadecaazapentapentacontan-55-amido)-8-(carboxymethyl)-2-(hydroxymethyl)-5,11-bis(2-(methylthio)ethyl)-4,7,10,13,16,19,22-heptaoxo-14-(4-(phosphonooxy)benzyl)-3,6,9,12,15,18,21-heptaazapentacosanedioic acid

(2S,5S,8S,11S,14S,23S)-23-((6S,9S,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54S)-21,45-bis((1H-indol-3-yl)methyl)-1,6-diamino-30-(2-amino-2-oxoethyl)-9,27-bis(3-amino-3-oxopropyl)-15,42,48,51-tetrakis(4-aminobutyl)-24-benzyl-12,18-di((S)-sec-butyl)-33,36-bis(3-guanidinopropyl)-54-(hydroxymethyl)-1-imino-39-(2-(methylthio)ethyl)-7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52-hexadecaoxo-2,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53-heptadecaazapentapentacontan-55-amido)-8-(carboxymethyl)-2-(hydroxymethyl)-5,11-bis(2-(methylthio)ethyl)-4,7,10,13,16,19,22-heptaoxo-14-(4-(phosphonooxy)benzyl)-3,6,9,12,15,18,21-heptaazapentacosanedioic acid

产品编号 :
Cas No. :
包装规格 纯度 目录价 会员专享价 库存 数量
1mg 95% 询价
- +
5mg 95% 询价
- +
10mg 95% 询价
- +
25mg 95% 询价
- +
50mg 95% 询价
- +
100mg 95% 询价
- +
250mg 95% 询价
- +
晶智化学产品均仅供科研使用。在任何情况下,我们均不提供用于动物或人体用途的产品或服务。

基础信息

CAS No.

1236188-16-1

英文名称

(2S,5S,8S,11S,14S,23S)-23-((6S,9S,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54S)-21,45-bis((1H-indol-3-yl)methyl)-1,6-diamino-30-(2-amino-2-oxoethyl)-9,27-bis(3-amino-3-oxopropyl)-15,42,48,51-tetrakis(4-aminobutyl)-24-benzyl-12,18-di((S)-sec-butyl)-33,36-bis(3-guanidinopropyl)-54-(hydroxymethyl)-1-imino-39-(2-(methylthio)ethyl)-7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52-hexadecaoxo-2,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53-heptadecaazapentapentacontan-55-amido)-8-(carboxymethyl)-2-(hydroxymethyl)-5,11-bis(2-(methylthio)ethyl)-4,7,10,13,16,19,22-heptaoxo-14-(4-(phosphonooxy)benzyl)-3,6,9,12,15,18,21-heptaazapentacosanedioic acid

别名

740 Y-P;RQIKIWFQNRRMKWKKSDGGYMDMS (Modifications: Tyr-21 = pTyr);PDGFR 740Y-P;740 Y-P, >96%;740 Y-P,740YPDGFR,PDGFR 740Y-P, >96%;740YPDGFR;L-Serine, L-arginyl-L-glutaminyl-L-isoleucyl-L-lysyl-L-isoleucyl-L-tryptophyl-L-phenylalanyl-L-glutaminyl-L-asparaginyl-L-arginyl-L-arginyl-L-methionyl-L-lysyl-L-tryptophyl-L-lysyl-L-lysyl-L-seryl-L-α-aspartylglycylglycyl-O-phosphono-L-tyrosyl-L-methionyl-L-α-aspartyl-L-methionyl-;740 Y-P (PDGFR 740Y-P)

标准英文名

(2S,5S,8S,11S,14S,23S)-23-((6S,9S,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42S,45S,48S,51S,54S)-21,45-bis((1H-indol-3-yl)methyl)-1,6-diamino-30-(2-amino-2-oxoethyl)-9,27-bis(3-amino-3-oxopropyl)-15,42,48,51-tetrakis(4-aminobutyl)-24-benzyl-12,18-di((S)-sec-butyl)-33,36-bis(3-guanidinopropyl)-54-(hydroxymethyl)-1-imino-39-(2-(methylthio)ethyl)-7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52-hexadecaoxo-2,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53-heptadecaazapentapentacontan-55-amido)-8-(carboxymethyl)-2-(hydroxymethyl)-5,11-bis(2-(methylthio)ethyl)-4,7,10,13,16,19,22-heptaoxo-14-(4-(phosphonooxy)benzyl)-3,6,9,12,15,18,21-heptaazapentacosanedioic acid

分子式

C141H222N43O39PS3

分子量

3270.76

精确分子量

3268.56

SMILES

CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)NCC(=O)N[C@@H](CC1=CC=C(OP(=O)(O)O)C=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O

标准SMILES

C[C@@H](CC)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC1C=CC=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CC1C=CC(=CC=1)OP(O)(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O

用途

740Y-P (PDGFR 740Y-P) is a cell-permeable PI3K phosphopeptide activator; it stimulates mitogenic responses specifically in muscle cells; promotes neuronal cell survival via the PI3K-Akt signaling cascade in a concentration-dependent manner without requiring insulin; reduces ROS levels in Aβ(25-32)-treated hippocampal tissues and enhances AKT and PI3K phosphorylation in an Alzheimer’s disease (AD) rat model following intraperitoneal administration (10 mg/kg for 6 weeks).

InChIKey

XCGMILZGRGEWHL-QYGSNONCSA-N

安全信息

SureRoute逆合成路线

1.  1236188-16-1 逆合成路线 1

—
—
ACZCTE584
1236188-16-1
来源: SureRoute

2.  1236188-16-1 逆合成路线 2

—
—
ACZCTE584
1236188-16-1
来源: SureRoute

3.  1236188-16-1 逆合成路线 3

—
—
ACZCTE584
1236188-16-1
来源: SureRoute
评论 0
我是晶智Agent,
您的化学小助手